Evidence map›Paper›PMID 39191501›Full record

ArticleCancer genomics & proteomics

DNA Methylation in Recurrent Glioblastomas: Increased TEM8 Expression Activates the Src/PI3K/AKT/GSK-3β/B-Catenin Pathway.

Paramita Kundu, Ruchi Jain, Nandaki Nag Kanuri, Arivazhagan Arimappamagan, Vani Santosh, Paturu Kondaiah

Abstract read
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Promoter Methylation-Expression Coupling of Gliogenesis Genes inInternational journal of molecular sciences · 2026
    Article
  5. Article
  6. Article
  7. Elevated expression ofFrontiers in molecular biosciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paramita KunduDepartment of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India.
Ruchi JainDepartment of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India.
Nandaki Nag KanuriDepartment of Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India.
Arivazhagan ArimappamaganDepartment of Neurosurgery, National Institute of Mental Health and Neurosciences, Bangalore, India.
Vani SantoshDepartment of Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India.
Paturu KondaiahDepartment of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India; paturu@iisc.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimGlioblastomas (GBM) are infiltrative malignant brain tumors which mostly recur within a year's time following surgical resection and chemo-radiation therapy. Studies on glioblastoma cells following radio-chemotherapy, have been demonstrated to induce trans-differentiation, cellular plasticity, activation of DNA damage response and stemness. As glioblastomas are heterogenous tumors that develop treatment resistance and plasticity, we investigated if there exist genome-wide DNA methylation changes in recurrent tumors. MATERIALS AND

methodsUtilizing genome-wide DNA methylation arrays, we compared the DNA methylation profile of 11 primary (first occurrence) tumors with 13 recurrent (relapsed) GBM, to delineate the contribution of epigenetic changes associated with therapy exposure, therapy resistance, and relapse of disease.

resultsOur data revealed 1,224 hypermethylated- and 526 hypomethylated-probes in recurrent glioblastomas compared to primary disease. We found differential methylation of solute carrier and ion channel genes, interleukin receptor/ligand genes, tumor-suppressor genes and genes associated with metastasis. We functionally characterized one such hypomethylated-up-regulated gene, namely anthrax toxin receptor 1/tumor endothelial marker 8 (ANTXR1/TEM8), whose expression was validated to be significantly up-regulated in recurrent glioblastomas compared to primary tumors and confirmed by immunohistochemistry. Using overexpression and knockdown approaches, we showed that TEM8 induces proliferation, invasion, migration, and chemo-radioresistance in glioblastoma cells. Additionally, we demonstrated a novel mechanism of β-catenin stabilization and activation of the β-catenin transcriptional program due to TEM8 overexpression via a Src/PI3K/AKT/GSK3β/β-catenin pathway.

conclusionWe report genome-wide DNA methylation changes in recurrent GBM and suggest involvement of the TEM8 gene in GBM recurrence and progression.

Indexed as

DNA MethylationGlioblastomaMicrofilament ProteinsReceptors, Cell SurfaceSignal Transductionbeta CateninCell Line, TumorHumansRecurrenceANTXR1 protein, humanbeta CateninMicrofilament ProteinsReceptors, Cell SurfaceDNA methylationglioblastomarecurrenceresistancetumor endothelial marker 8β-catenin

Identifiers

PMID39191501
PMCPMC11363927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.